Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review

ConclusionAvailable economic evaluations show that using BV as front-line treatment or consolidation therapy is not cost-effective based on specific ICER thresholds for patients with HL or R/R HL. To decide on this orphan drug, we should consider other factors such as existence of alternative treatment options, clinical benefits, and disease burden.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research